

Table 5: Drug doses used for desensitization in patients with living donor kidney transplantation after desensitization and renal biopsy findings of patients who had rejection.

Patient No	Desensitisation Protocol			Acute Rejection									
	IVIG	Rituximab	PP	Type	C4d	g	i	v	t	cg	ci	ct	cv
1.	120	600	3	None									
2.	120	600	5	None									
3.	0	0	3	AAMR	++	1	2	0	1	0	0	0	0
4.	80	500	4	None									
5.	145	680	7	TCMR	(-)	0	2	0	0	0	0	0	0
6.	140	0	0	cAAMR	++	1	2	0	2	0	2	2	0
7.	140	700	0	None									
8.	130	0	4	None									
9.	120	0	0	None									
10.	140	700	4	None									
11.	120	600	7	None									
12.	55	700	3	None									
13.	90	500	3	AAMR	(-)	2	2	2	2	0	0	0	0
14.	110	600	14	None									
15.	120	0	3	None									
16.	120	0	12	None									

IVIG: intravenous immunoglobulin, PP: Plasmapheresis, AAMR: Acute antibody mediated rejection, TCMR: T Cell Mediated Rejection, cAAMR: Chronic active antibody mediated rejection, g: glomerulitis, i: interstitial inflammation, v: intimal arteritis, t: tubulitis, cg: chronic glomerulopathy, ci: chronic interstitial inflammation, ct: chronic tubular atrophy, cv: vascular intimal sclerosis.